Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy

Molecular Therapy

Volumn 3, Issue 5, 2001, Pages 768-778

  Rahman, Amena ^a   Tsai, Van ^b   Goudreau, Ann ^a   Shinoda, Jeremy Y ^a   Wen, Shu Fen ^a   Ramachandra, Muralidhara ^a   Ralston, Rob ^a   Maneval, Dan ^b   LaFace, Drake ^b   Shabram, Paul ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Canji   (United States)

Author keywords

Capsid columns; Depletion; Empty rAd vector; Green fluorescent protein rAd vector; Immunopheresis; Neutralizing antibodies; Recombinant adenovirus; Transduction efficiency; galactosidase rAd vector

Indexed keywords

BETA GALACTOSIDASE; STRUCTURAL PROTEIN; VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; IN VITRO STUDY; IN VIVO STUDY; LIVER; MODEL; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; SCID MOUSE; VIRION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; MIRIDAE; MURINAE;

EID: 17844394733     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0316     Document Type: Article

References (51)

1. Adenoviridae: The viruses and their replication
2. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography
3. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles
4. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic transmembrane conductance regulator gene in the lung
5. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients
6. P53 tumor suppressor gene therapy for cancer
7. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma
8. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
9. Immunologic barriers to hepatic adenoviral gene therapy for transplantation
10. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
11. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer
12. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
13. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
14. Gene therapy: Adenovirus vectors
15. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses
16. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
17. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
18. Circumvention of immunity to the adenovirus major coat protein hexon
19. Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity
20. The murine cellular immune response to adenovirus type 5
21. Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1A is immunodominant in H-2b, but not in H-2d or H-2k mice
22. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
23. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors
24. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
25. Immune responses to reporter proteins and high viral dose limit duration of expression with adeno-viral vectors: Comparison of E2a wild type and E2a deleted vectors
26. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
27. TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung
28. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression
29. Circumventing the immune response to adenovirus-mediated gene therapy
30. Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus-induced lg subclass shifts
31. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo
32. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo
33. Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver
34. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity
35. Successful gene transfer to the porcine liver in vivo with an adenoviral vector
36. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer
37. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver
38. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway
39. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle
40. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4lg
41. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4lg enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver
42. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma
43. The Prosorba column for treatment of refractory rheumatoid arthritis: A randomized, double-blind, sham-controlled trial
44. p53 gene therapy in a rat model of hepatocellular carcinoma: Intra-arterial delivery of a recombinant adenovirus
45. Adenovirus-based expression vectors and recombinant vaccines
46. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver
47. Use of human adenovirus-based vectors for antigen expression in animals
48. Reagent
49. Bias in murine lgG isotype immobilisation: Implications for lgG glycoform analysis ELISA procedures
50. Human immunoglobulins
51. Therapeutic apheresis